Metformin, a drug prescribed for type 2 diabetes, breast cancer cells appear to starve by denying them access to taste good nutrients. relationship between metformin and breast cancer treatment has been studied for several years and has been tested in the laboratory together with Adriamycin on breast cancer stem cells, appears to increase the efficiency of Adriamycin in treatment of hormone-sensitive breast cancer, as well as HER2-positive and triple negative breast tumors.
A new study supported by Breakthrough Breast Cancer has been to develop a test to determine which patients with breast cancer would benefit most from a plan for treatment with metformin. study led by Dr. Michael Lisanti Thomas Jefferson University and Dr. Anthony Howell of the University of Manchester, Dr. Howell explained that "some cancer cells are nourished with healthy cells, we discovered an agent would block that is Metforminen common drug used to treat diabetes."When the question of how this will help breast cancer patients, he replied, "" potential advantage is that it will stop the cancer cell that is administered through the normal cell, and then the cell cancer grow. "Dr. Howell also noted that Metformin is relatively cheap, especially when compared to conventional chemotherapy drugs.
Women who have been diagnosed with aggressive forms of breast cancer may someday be tested to see if Metformin is going to stop the growth and repeated their cancer; if their tumor responds drug such as diabetes, then they can take personal treatment, in particular on the basis of the type of tumor and the fuel required to grow Dr. Howell said, "it is incredibly exciting. It is a step towards that each patient receives the right treatment for them-we call personalized medicine. We look at a new way to distinguish patients on the basis that respond well to treatments we have, and need something else. "
Metformin is readily available and each pill costs around 10 pence in the UK or about 16 cents in the United-States, the results of the study and Howells Lisanti, published in the journal cell cycle.
No comments:
Post a Comment